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LETTERS
M. genavense infections occur only 
rarely in persons other than AIDS 
patients (as in the present case), but 
they always occur in immunocom-
promised persons (7,8). To date, only 
1 case of disseminated infection has 
been reported in a solid-organ (kid-
ney) transplant recipient; the diag-
nosis was made by molecular iden-
tiﬁ  cation in isolates from blood and 
marrow cultures. That patient died of 
complications from M. genavense in-
fection (9). Because M. genavense is 
a fastidious organism, the infections 
it causes are difﬁ  cult to diagnose and 
their frequency is probably underes-
timated, which may change with in-
creased use of direct molecular bio-
logical methods.
Optimal treatment of M. ge-
navense infections has not been es-
tablished (10). Experience with M. 
genavense infections in AIDS patients 
and with other nontuberculous myco-
bacteria infections in solid-organ trans-
plant recipients suggests that at least 
2 antimicrobial drugs should be used 
for a prolonged period; when possible, 
immunosuppressive drugs should be 
concurrently reduced (1,3,6,10). Out-
come of nontuberculous mycobacte-
ria infections in transplant patients is 
highly variable (1,5) but was satisfac-
tory in the present patient, who was 
treated with quintuple antimicrobial-
drug therapy and reduced immuno-
suppressive therapy.
This case of a disseminated infec-
tion due to M. genavense in a heart 
transplant recipient was diagnosed 
early. Universal 16S rRNA gene se-
quencing after ampliﬁ  cation  directly 
from intestinal biopsy specimens en-
abled fast diagnosis and appropriate 
management.
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Isolation of Novel 
Adenovirus from 
Fruit Bat (Pteropus 
dasymallus 
yayeyamae)
To the Editor: Bats are thought to 
be one of the most important reservoirs 
for viruses such as Nipah virus, severe 
acute respiratory syndrome (SARS) 
coronavirus, and Ebola virus (1). 
These pathogens became known after 
extensive surveys of bats following 
outbreaks. As a ﬁ  rst step in investigat-
ing unidentiﬁ  ed pathogens in bats and 
to help forecast the potential threat of 
emerging infectious diseases, we tried 
to isolate and characterize viruses that 
persistently infect bats. In the process, 
we isolated a novel adenovirus from a 
fruit bat in Japan. 
Pteropus dasymallus yayeyamae, 
or Ryukyu ﬂ  ying fox, is a fruit bat of 
Japan. With the permission of the gov-
ernor of Okinawa, we caught 1 adult 
male bat of this species and used its 
spleen and kidneys to establish pri-
mary cell cultures. On the 4th passage 
of the primary adherent cells derived 
from the spleen, a cytopathic effect 
(CPE) appeared without any visible 
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microbe, indicating that the cell culture 
contained a virus. The virus, tentatively 
named Ryukyu virus 1 (RV1), caused 
apparent CPE on primary kidney cells 
derived from a Ryukyu ﬂ  ying  fox 
and on our established bat kidney T1 
(BKT1) cells, which were derived from 
the kidney of a horseshoe bat (Rhinolo-
phus ferrumequinum) and transformed 
with expression plasmid DNA encod-
ing the large T antigen of replication 
origin-defective simian virus 40. 
To identify the virus, RV1, we 
applied the rapid determination of vi-
ral RNA (RDV) system version 1.0 
(2). However, no viral nucleic acid 
sequence was detected from an RNA 
sample in the RV1-infected BKT1 
cells. For detection of viral DNA, we 
developed a system for rapid determi-
nation of viral DNA sequences (RDV-
D) by minor modiﬁ  cation to the RDV 
system for RNA viruses (2–4). The re-
sults indicated that 2 of the fragments 
were homologous to the gene encod-
ing the precursor of terminal protein 
(pTP) of adenoviruses. Further RDV-
D analysis showed that 6 fragments 
(139 bp, DDBJ/EMBL/GenBank ac-
cession no. AB302970) were homolo-
gous to the pTP gene and that another 
6 fragments (316bp, DDBJ/EMBL/
GenBank accession no. AB302971) 
were homologous to the gene encod-
ing the precursor of protein VI (pVI) 
of adenoviruses. These results indicat-
ed that RV1 must belong to the family 
Adenoviridae.
To further conﬁ  rm that RV1 iso-
late was an adenovirus, we used PCR 
and sequencing. We performed the 
ﬁ  rst reaction with the outer primer pair 
(polFouter and polRouter) of a nested 
PCR method, targeting the viral DNA 
polymerase gene with highly degener-
ate consensus primers that have been 
described recently (5). A fragment of 
≈550 bp was ampliﬁ  ed from RV1 as 
well as from human adenoviruses-
1, -3, -4, and -7 (data not shown). 
Sequence analysis of the ampliﬁ  ed 
product (DDBJ/EMBL/GenBank ac-
cession no. AB303301) showed that 
RV1 was homologous to tree shrew 
adenovirus 1 (70.0% amino acid se-
quence identity), porcine adenovi-
rus 5 (69.2%), canine adenovirus 1 
(68.9%), human adenoviruses-3, -16, 
-21 and -50 (68.9%), and other viruses 
(>64.8%) in genus Mastadenovirus, 
but less homologous (46.7%–57.8%) 
to viruses in other genuses, Siadenovi-
rus, Aviadenovirus, and Atadenovirus. 
In addition, a phylogenic tree based on 
amino acid sequences indicated that 
RV1 belongs to family Adenoviridae, 
genus Mastadenovirus (Figure). 
Electron microscopy of RV1-in-
fected BKT1 cells indicated that RV1 
accumulated in the nucleus and that 
the size of capsids was 60–70 nm (data 
not shown). Restriction endonuclease 
analysis of the RV1 genome indicated 
that the genome was ≈20–30 kbp (data 
not shown). These features are consis-
tent with RV1 being an adenovirus. 
Until now, a number of RNA vi-
ruses have been isolated from bats, 
but isolation of DNA virus is rare (1). 
The isolation of the novel adenovirus 
seems to be possible because of usage 
of the primary cells originated from 
the host; DNA viruses might have 
more restricted host range than RNA 
viruses and require host-originated 
cells for the growth. In addition, our 
success in DNA virus isolation might 
have resulted from usage of the adult 
animal latently and persistently infect-
ed with DNA viruses such as adenovi-
rus and herpesvirus.
In conclusion, we isolated a novel 
virus from a fruit bat. This virus was 
isolated from a healthy bat, which 
suggests that the virus may persistent-
ly infect fruit bats. Although its patho-
genicity for humans is still unknown, 
knowledge of RV1 will be useful in 
epidemiologic studies of infectious 
diseases emerging from bats because 
persistently infecting viruses might be 
isolated together with primary patho-
gens. We are planning to establish cell 
lines from bats and isolate more virus-
es from persistently infected bats. 
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Figure. Phylogeny of adenoviruses based on analysis of partial amino acid sequences 
of DNA polymerase protein. Trees were estimated by using the neighbor-joining method 
based on the amino acid pairwise distance and MEGA 4.0 software (www.megasoftware.
net). Numbers represent percentage bootstrap support (100 replicates). LETTERS
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Fluoroquinolone-
Resistant Group 
B Streptococci in 
Acute Exacerbation 
of Chronic 
Bronchitis 
To the Editor: Fluoroquinolones 
(FQs) that are active against strep-
tococcal species (e.g., levoﬂ  oxacin 
and moxiﬂ  oxacin) have been recom-
mended by numerous national health 
authorities and international organiza-
tions for treating acute exacerbations 
of chronic bronchitis and pneumonia 
in adults (1). However, use of these 
antimicrobial drugs for treating com-
munity-acquired infections has led to 
an increase in FQ-resistant strains in 
bacteria such as Streptococcus pneu-
moniae. Group B streptococci (GBS, 
e.g.,  S.  agalactiae) are the leading 
cause of invasive infections (pneumo-
nia, septicemia, and meningitis) in ne-
onates. GBS are also associated with 
bacteremia, endocarditis, and arthritis, 
and are responsible for deaths and ill-
ness in nonpregnant women with un-
derlying diseases and in elderly adults 
(2). We describe, to our knowledge, 
the ﬁ  rst GBS clinical isolate in France 
resistant to FQ; the isolate was from a 
patient treated with levoﬂ  oxacin. 
GBS CNR0717 strain was iso-
lated as the predominant bacterium 
in a culture (>107 CFU/mL) from 2 
purulent sputum samples from an 80-
year-old man (leukocytes >25, epithe-
lial cells <10) obtained 8 days apart. 
This patient was treated for 2 weeks 
with levoﬂ   oxacin, 750 mg/day, for 
acute exacerbation of chronic bron-
chitis. No other relevant respiratory 
bacterial pathogens were present in 
these samples. GBS CNR0717, a 
capsular serotype IV strain, was sus-
pected to have reduced susceptibil-
ity to FQs because no inhibition zone 
was observed around disks contain-
ing norﬂ  oxacin and peﬂ  oxacin disks, 
and reduced diameters were observed 
around disks containing ciproﬂ  oxacin 
and levoﬂ  oxacin. Antibiograms were 
performed according to recommen-
dations of the Clinical and Labora-
tory Standards Institute (3) on Mueller 
Hinton agar (Bio-Rad, Marnes la Co-
quette, France) supplemented with 5% 
horse blood. This strain was suscep-
tible to all other antimicrobial drugs 
usually active against GBS (penicillin, 
erythromycin, clindamycin, tetracy-
cline, rifampicin, vancomycin) and 
showed low-level resistance against 
aminoglycosides. MICs for 6 FQs 
(Table) indicate that GBS CNR0717 
was highly resistant to peﬂ  oxacin and 
norﬂ   oxacin, with MICs >64 mg/L, 
and showed increased MICs for cip-
roﬂ  oxacin, sparﬂ  oxacin, levoﬂ  oxacin, 
and moxiﬂ  oxacin. No reduction of FQ 
MICs was observed with reserpine (10 
mg/L), which indicated that resistance 
to FQ was not caused by an active ef-
ﬂ  ux pump system. 
Three major mutations have been 
reported for FQ resistance in strepto-
cocci at codon positions 81 in gyrA and 
79 or 83 in parC (4). DNA sequence 
analysis of these regions showed a 
mutation in parC (Ser 79 → Tyr) but 
not in the wild-type susceptible strain 
(NEM316). No mutation was detect-
ed in the gyrA gene. FQ resistance in 
streptococci is acquired through a step-
wise process and has been extensively 
studied in S. pneumoniae. First-step 
mutants conferring low-level resis-
tance generally result from mutations 
in either gyrA or parC. There is also 
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Table. MICs of fluoroquinolones for strains of group B streptococci (GBS), France 
MIC (mg/L)* 
Strain Pef Nor Cip Spa Lev Mox
G B S  C N R 0 7 0 1 7   > 6 4 > 6 4 4141
GBS NEM316  16 8 2 0.5 1 0.25
*Pef, pefloxacin; Nor, norfloxacin; Cip, ciprofloxacin; Spa, sparfloxacin; Lev, levofloxacin; Mox, 
moxifloxacin. 
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